Key points are not available for this paper at this time.
Abstract Extracellular vesicles (EVs) are particles released from cells that facilitate intercellular communication and have tremendous diagnostic and therapeutic potential. Bulk assays lack the sensitivity to detect rare EV subsets relevant to disease, and while single EV analysis techniques remedy this, they are often undermined by complicated detection schemes and prohibitive instrumentation. To address these issues, a microfluidic technique for EV characterization called “ ca tch and d isplay for l iquid b iopsy (CAD‐LB)” is proposed. In this method, minimally processed samples are pipette‐injected and fluorescently labeled EVs are captured in the nanopores of an ultrathin membrane. This enables the rapid assessment of EV number and biomarker colocalization by light microscopy. Here, nanoparticles are used to define the accuracy and dynamic range for counting and colocalization. The same assessments are then made for purified EVs and for unpurified EVs in plasma. Biomarker detection is validated using CD9 and Western blot analysis to confirm that CAD‐LB accurately reports relative protein expression levels. Using unprocessed conditioned media, CAD‐LB captures the known increase in EV‐associated ICAM‐1 following endothelial cell cytokine stimulation. Finally, to demonstrate CAD‐LB's clinical potential, EV biomarkers indicative of immunotherapy responsiveness are successfully detected in the plasma of bladder cancer patients treated with immune checkpoint blockade.
Walker et al. (Wed,) studied this question.